Santarus (SNTS) Submits IND to U.S. FDA to Begin Phase III of Rifamycin SV MMX
Tweet Send to a Friend
Santarus, Inc. (NASDAQ: SNTS) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
